# HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections

> **NCT01384734** · PHASE2 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 254 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus

## Interventions

- **DRUG:** BMS-663068 400 mg
- **DRUG:** BMS-663068 800 mg
- **DRUG:** BMS-663068 600 mg
- **DRUG:** BMS-663068 1200 mg
- **DRUG:** Raltegravir 400 mg
- **DRUG:** Tenofovir 300 mg
- **DRUG:** Ritonavir 100 mg
- **DRUG:** Atazanavir 300 mg

## Key facts

- **NCT ID:** NCT01384734
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07-26
- **Primary completion:** 2013-02-18
- **Final completion:** 2017-05-12
- **Target enrollment:** 254 (ACTUAL)
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01384734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01384734, "HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01384734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*